Organization (Industry)
Kyowa Kirin (Japan)
ClinicalTrials.gov lists Kyowa Kirin (Japan) as lead sponsor of 195 trials, counting the companies grouped under it. Kyowa Kirin (Japan) itself has 172 active development programs and 36 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Kyowa Hakko Kirin, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Kyowa Kirin (Japan) and 1 company grouped under it: 195 lead-sponsored trials (195 its own, 0 in the grouped companies) and 5 legal-entity registrations (4 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Kyowa Hakko Kirin (Singapore) | 0 | 1 |
Disease areas (115)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Parkinson Disease | 31 |
| Bone Diseases, Metabolic | 20 |
| Malnutrition | 20 |
| Vitamin D Deficiency | 20 |
| Familial Hypophosphatemic Rickets | 19 |
Showing 5 of 115 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 8 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 13 |
| 2020 | 4 |
| 2019 | 23 |
| 2018 | 7 |
| 2017 | 9 |
Showing 10 of 26 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 175 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (172)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| KK8398 | Dwarfism | Phase 3 | 1 |
| KK8398 | Achondroplasia | Phase 3 | 1 |
| Istradefylline | Parkinson Disease | Phase 3 | 14 |
| Tenapanor | Hyperphosphatemia | Phase 3 | 7 |
| Mogamulizumab | Lymphoma | Phase 3 | 6 |
Showing 5 of 172 active programs.
Approved assets (36)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Burosumab | 18 |
| Brodalumab 210mg SC | 1 |
| KHK4827-Active | 1 |
| Istradefylline | 17 |
| Mogamulizumab | 13 |
Showing 5 of 36 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 78% hit target (n=54) | 57% on time (n=49) |
Journals published in (73)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 7 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 7 |
| The Journal of clinical endocrinology and metabolism | 6 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 5 |
| Calcified tissue international | 4 |
Showing 5 of 73 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 319 | 33 | 2025-11-11 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
Organization relationships (17)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Kyowa Hakko Kirin UK, Ltd. | Co sponsors trial with | 4 |
| Yale University | Co sponsors trial with | 2 |
| Universitätsklinikum Würzburg | Co sponsors trial with | 2 |
| Duke University | Co sponsors trial with | 1 |
| Moffitt Cancer Center | Co sponsors trial with | 1 |
Showing 5 of 17 relationships.
Latest dated events (547)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-07-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 547 events.
Biomarker capability evidence (564)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 564 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.